Table 3.
Total | Age—categories in years | |||||||
---|---|---|---|---|---|---|---|---|
(N = 15 037) | 18–24 (N = 2076) | 25–34 (N = 3725) | 35–44 (N = 3459) | 45–54 (N = 2846) | 55–64 (N = 2151) | 65–74 (N = 662) | ≥75 (N = 118) | |
GAD-7 | ||||||||
<5 | 8289 (55.1%) | 915 (44.1%) | 2045 (54.9%) | 1836 (53.1%) | 1645 (57.8%) | 1306 (60.7%) | 461 (69.6%) | 81 (68.7%) |
≥5 | 4226 (28.1%) | 618 (29.8%) | 1026 (27.5%) | 1035 (29.9%) | 772 (27.1%) | 593 (27.6%) | 154 (23.3%) | 28 (23.7%) |
≥10 | 1476 (9.8%) | 307 (14.8%) | 377 (10.1%) | 347 (10.0%) | 262 (9.2%) | 147 (6.8%) | 29 (4.4%) | 7 (5.9%) |
≥15 | 1046 (7.0%) | 236 (11.4%) | 277 (7.4%) | 241 (7.0%) | 167 (5.9%) | 105 (4.9%) | 18 (2.7%) | 2 (1.7%) |
PHQ-2 | ||||||||
<3 | 12 880 (85.7%) | 1 529 (73.7%) | 3 202 (86.0%) | 3 005 (86.9%) | 2 520 (88.5%) | 1 912 (88.9%) | 606 (91.5%) | 106 (89.8%) |
≥3 | 2 157 (14.3%) | 547 (26.3%) | 523 (14.0%) | 454 (13.1%) | 326 (11.5%) | 239 (11.1%) | 56 (8.5%) | 12 (10.2%) |
DT | ||||||||
<4 | 5 238 (34.8%) | 676 (32.6%) | 1282 (34.4%) | 1024 (29.6%) | 986 (34.6%) | 831 (38.6%) | 367 (55.4%) | 72 (61.0%) |
≥4 | 9799 (65.2%) | 1400 (67.4%) | 2443 (65.6%) | 2435 (70.4%) | 1860 (65.4%) | 1320 (61.4%) | 295 (44.6%) | 46 (39.0%) |
COVID-19-related fear | ||||||||
<5 | 6170 (41.0%) | 930 (44.8%) | 1709 (45.9%) | 1348 (39.0%) | 1115 (39.2%) | 795 (37.0%) | 232 (35.0%) | 41 (34.7%) |
≥5 | 8867 (59.0%) | 1146 (55.2%) | 2016 (54.1%) | 2111 (61.0%) | 1731 (60.8%) | 1356 (63.0%) | 430 (65.0%) | 77 (65.3%) |
Note: GAD-7 = Generalized Anxiety Disorder Scale-7, sum scores of ≥5, ≥10 and ≥15 indicate mild, moderate and severe generalized anxiety symptoms, respectively; PHQ-2 = Patient Health Questionnaire-2, sum scores of ≥3 indicate major depression symptoms; DT = Distress Thermometer, a score ≥4 indicates elevated psychological distress. COVID-19-related fear, ≥5 indicate elevated COVID-19-related fear.